The CCL2-CCR2 axis was found to reduce apoptosis through inhibition of caspase-3 and poly(ADP-ribose) polymerase (PARP), indicating that CCL2 is potentially a key contributor to cabazitaxel resistance in prostate cancer cells [61]. Here, CCR2 is linked to Familial prostate cancer.